title: Relation between mitral regurgitation and platelet activation.
abstract: OBJECTIVE
  This study sought to examine the effect of mitral regurgitation (MR) on platelet activation in patients with mitral valve prolapse (MVP) or rheumatic MR.
  
  
  BACKGROUND
  MVP and rheumatic MR are associated with an increased incidence of thromboembolic events. Although the underlying causes are not clear, increased platelet activation has been suggested as one of the pathogenic mechanisms. Results of previous studies that have investigated the relation between MVP and platelet activation are controversial. Whether the presence of MR in patients with mitral valve disease is associated with platelet activation remains unclear.
  
  
  METHODS
  We studied platelet activation by measuring the plasma level of platelet factor 4 (PF4) and beta-thromboglobulin (BTG) in 16 patients with MVP, 12 patients with rheumatic MR and 25 control subjects. A detailed echocardiographic examination, including M-mode measurement and color Doppler flow mapping to detect the presence and severity of MR was performed.
  
  
  RESULTS
  Patients and control subjects were matched for gender, age and left ventricular ejection fraction. Eight (50%) of 16 patients with MVP had MR. Patients with MVP and MR and patients with rheumatic MR had a significantly larger left atrial diameter. Mean log plasma levels of PF4 and BTG were significantly higher in patients with MVP and MR and patients with rheumatic MR than in control subjects (1.17 +/- 0.22 and 0.93 +/- 0.23 IU/ml vs. 0.52 +/- 0.34 IU/ml, p < 0.01; 1.70 +/- 0.21 and 1.53 +/- 0.15 IU/ml vs. 1.37 +/- 0.15 IU/ml, p < 0.05, respectively) but were comparable in patients with MVP and no MR and control subjects. Plasma levels of PF4 and BTG were positively correlated with the severity of MR, as assessed by a semiquantitative method (r = 0.59, p = 0.0001; r = 0.60, p = 0.0001, respectively). Increasing age and left atrial enlargement were not related to platelet activation.
  
  
  CONCLUSIONS
  MR in mitral valve disease was associated with systemic platelet activation. MVP itself was not associated with increased platelet activation. The degree of platelet activation was positively correlated with the severity of MR and was independent of the underlying etiology of mitral valve disease, age and left atrial size. The possibility of a higher incidence of thromboembolism and the role of antiplatelet agents in such patients will require further studies to determine.
authors.affiliation: Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
authors.forename: H F
authors.initials: HF
authors.lastname: Tse
authors.forename: C P
authors.initials: CP
authors.lastname: Lau
authors.forename: G
authors.initials: G
authors.lastname: Cheng
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D004452:Echocardiography; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008944:Mitral Valve Insufficiency / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging; D008945:Mitral Valve Prolapse / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging; D015539:Platelet Activation; D010978:Platelet Factor 4 / Q000032:analysis; D012214:Rheumatic Heart Disease / Q000097:blood* / Q000150:complications / Q000000981:diagnostic imaging; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology; D001620:beta-Thromboglobulin / Q000032:analysis
chemical_list: D001620:beta-Thromboglobulin; D010978:Platelet Factor 4